Your browser doesn't support javascript.
loading
[The early therapeutic effect of low-dose clarithromycin for chronic nasosinusitis with nasal polyps].
Song, Y; Chen, R; Fu, M Y.
Afiliación
  • Song Y; Department of Otorhinolaryngology Head and Neck Surgery, Zhongshan Hospital of Sun Yat-Sen University,Zhongshan People's Hospital,Zhongshan,528400,China.
Article en Zh | MEDLINE | ID: mdl-30669202
ABSTRACT

Objective:

To observe the early therapeutic effect of low-dose clarithromycin for chronic nasosinusitis with nasal polyps.

Method:

Clarithromycin was 250mg a day and budesonide nasal apray was once a day.Follow-up time was 12 weeks. The number of postoperative clarithromycin+budesonide nasal apray treatment group and simple budesonide nasal apray treatment group were forty. The early therapeutic effect of patients was assessed by SNOT-20 and EAS score before treatment,2 weeks,4 weeks,8 weeks,and 12 weeks.

Result:

Before treatment,at 2 weeks and 12 weeks,there was no significant difference between the two groups in the results of the SNOT-20 score. But there were significant differences at 4 weeks and 8 weeks.Before treatment and at 12 weeks, there was no statistically significant difference between the two groups in the results of the EAS score.But there were significant differences at 2 weeks,4 weeks,and 8 weeks.

Conclusion:

The early use of low-dose clarithromycin has a definite curative effect on patients of chronic rhinosinusitis with nasal polyps.The larger randomized controlled trials were still needed to verify the specific mechanism and optimal dosage.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: Zh Revista: Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi Año: 2019 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: Zh Revista: Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi Año: 2019 Tipo del documento: Article País de afiliación: China